login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
EXELIXIS INC (EXEL) Stock News
USA
-
Nasdaq
- NASDAQ:EXEL -
US30161Q1040
-
Common Stock
41.8
USD
+0.2 (+0.48%)
Last: 12/17/2025, 1:24:56 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
EXEL Latest News, Press Relases and Analysis
All
Press Releases
2 days ago - By: Chartmill
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case
5 days ago - By: Chartmill
Exelixis Inc (NASDAQ:EXEL) Emerges as a Prime GARP Candidate with Strong Growth and Sound Valuation
2 days ago - By: Zacks Investment Research
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
5 days ago - By: Equity Insider
- Mentions:
ONCY
AGEN
CRDF
GILD
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
13 days ago - By: Zacks Investment Research
- Mentions:
MYGN
Why Is Exelixis (EXEL) Up 9% Since Last Earnings Report?
13 days ago - By: Zacks Investment Research
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
14 days ago - By: Exelixis, Inc.
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
15 days ago - By: Zacks Investment Research
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
16 days ago - By: The Motley Fool
- Mentions:
AXSM
2 Under-the-Radar Stocks to Buy Heading Into 2026
19 days ago - By: Zacks Investment Research
Here's Why Exelixis (EXEL) is a Strong Growth Stock
a month ago - By: Zacks Investment Research
Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention
a month ago - By: Zacks Investment Research
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
a month ago - By: Zacks Investment Research
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
a month ago - By: Exelixis, Inc.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
a month ago - By: Zacks Investment Research
- Mentions:
AMGN
MCD
LITE
Company News for Nov 6, 2025
a month ago - By: Zacks Investment Research
- Mentions:
ALKS
FOLD
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
a month ago - By: Zacks Investment Research
Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
a month ago - By: Zacks Investment Research
- Mentions:
BNGO
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
a month ago - By: Exelixis, Inc.
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: Benzinga
- Mentions:
KURA
SEE
HRMY
FOLD
...
Earnings Scheduled For November 4, 2025
a month ago - By: Benzinga
Preview: Exelixis's Earnings
2 months ago - By: Zacks Investment Research
- Mentions:
ADPT
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2 months ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
2 months ago - By: Exelixis, Inc.
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
2 months ago - By: Exelixis, Inc.
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet
2 months ago - By: Exelixis, Inc.
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
Please enable JavaScript to continue using this application.